PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 691 of 767

Advanced search
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Sound mind, sound place: ibasho and post-disaster mental health

PubMed Lancet RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Q&A: Ezekiel Emanuel's simple rules

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

BP-lowering drugs reduced major CV events to a similar extent in patients with or without isolated diastolic hypertension

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Risk

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

In MINOCA, stratified treatment guided by MINOCA cause vs. standard care improved angina status at 1 y

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

In sepsis, a tailored precision immunotherapy strategy improved organ function at 9 d

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

In patients with painful diabetic neuropathy, pregabalin does not differ from duloxetine for pain

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

In the ED, the Wells score plus age-adjusted D-dimer score ruled out DVT with a failure rate ≤0.8% at 3 mo

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

In patients with chronic lung disease, 4 existing PE diagnostic strategies were assessed

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

In adults with ADHD, atomoxetine, methylphenidate, and CBT reduce symptom severity and the drugs are less tolerable vs. control at 12 wk

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Summary for Patients: Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Risk

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

After ischemic stroke in patients receiving aspirin, switching to another antithrombotic regimen does not reduce recurrence

PubMed Annals of Internal Medicine RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia

PubMed Journal of Clinical Oncology RSSOriginal source
🇺🇸Industryzoetis.comTier 1 · Company source

ask our experts monoclonal antibodies explained

Watch our experts answer some common questions we’ve received from veterinarians about monoclonal an...

ZoetisOriginal source
🇯🇵Devicestel.comTier 1 · Company source

Products / Services

About Tokyo Electron's Products and Service News

Tokyo Electron (Life Science Tech)Original source
🇯🇵Industrypeptidream.comTier 1 · Company source

2026.04.06æ ªä¸»ç ä¼šã®Q&Aã‚’å ¬é–‹ã—ã¾ã—ãŸ

PeptiDreamOriginal source
🇺🇸Industryfinnegan.comTier 1 · Company source

Litigation Leaders: Finnegan’s Jennifer Roscetti on the Advantages of Being Fully Focused on IP

Finnegan IP (Life Sciences focus)Original source
🇺🇸Industryamgen.comTier 1 · Company source

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Pr...

Amgen (Global News)Original source
🇺🇸Industryir.ideayabio.comTier 1 · Company source

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low...

IDEAYA BiosciencesOriginal source
🇺🇸Industryinvestors.biogen.comTier 1 · Company source

biogen report first quarter 2026 financial results april 29 2026

Biogen NewsOriginal source
🇺🇸Industryinvestor.agios.comTier 1 · Company source

4/6/2026Press ReleaseAgios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETRead More

Agios PharmaceuticalsOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Canada's Yukon Territory publishes First Nations Cancer Strategy

PubMed Lancet Oncology RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

European Breast Cancer Conference 2026

PubMed Lancet Oncology RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Senators demand explanation for US Preventive Services Task Force halt

PubMed Lancet Oncology RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial

PubMed Lancet Infectious Diseases RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Concerns regarding study of spatial emanators for malaria control

PubMed Lancet Infectious Diseases RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Concerns regarding study of spatial emanators for malaria control - Authors' reply

PubMed Lancet Infectious Diseases RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial

PubMed Lancet RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Global burden of cancer in children and adolescents aged 0-19 years, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

PubMed Lancet RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Perioperative immunotherapy for resectable hepatocellular carcinoma - Authors' reply

PubMed Lancet RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Perioperative immunotherapy for resectable hepatocellular carcinoma

PubMed Lancet RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Clinical phenotyping improves choices of biologics in asthma - Authors' reply

PubMed Lancet RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Clinical phenotyping improves choices of biologics in asthma

PubMed Lancet RSSOriginal source
🌍Industrycuris.comTier 1 · Company source

Washington University School of Medicine

CurisOriginal source
🌍Industrymatinasbiopharma.comTier 1 · Company source

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Matinas BioPharmaOriginal source
🌍Medialemsurgical.comTier 2 · Direct publisher

The Democratization of Care: Scaling the Artisan Surgeon through Physical AI

LEM Surgical (Dynamis Spine Robot)Original source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a c...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multiple sclerosis medicine glatiramer acetate (Copaxone, Glatopa)

FDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multip...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)

FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medi...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system)

The antinausea patch Transderm Scōp (scopolamine transdermal system) can increase body temperature a...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use

FDA is requiring safety labeling changes for opioid pain medicines to further emphasize and characte...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine

FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozap...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)

FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leq...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa

FDA has notified application holders for all drug products containing carbidopa/levodopa that the Ag...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis

FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

Generic Drug User Fee Amendments

This page features news and information for industry and stakeholders about GDUFA, its fee structure...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

As They Grow: Teaching Your Children How To Use Medicines Safely

How to start talking to your children about medicines and how you make medicine decisions for yourse...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)

Stay informed on FDA updates and press announcements about recalls involving angiotensin II receptor...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

Stop - Learn - Go: Tips for Talking with Your Pharmacist to Learn How to Use Medicines Safely

Points to discuss with your pharmacist and other healthcare providers

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA Rare Disease Innovation Hub

FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and conne...

FDA Drug ApprovalsOriginal source
🇺🇸Regulatoryfda.govTier 1 · Regulatory source

FDA Issues Draft Guidance for Industry on the Design and Evaluation of Comparative Analytical Studies for Biosimilarity

CDER Statement

FDA Drug ApprovalsOriginal source
🇦🇹Regulatorybasg.gv.atTier 1 · Regulatory source

Cinglan 30 mg-Filmtabletten

Rückruf aufgrund verminderter Wirkstofffreisetzung

BASG AustriaOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings

PubMed Lancet Infectious Diseases RSSOriginal source
🇺🇰Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

The case for routine patient review in long COVID research

PubMed Lancet Infectious Diseases RSSOriginal source
🇺🇸Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Erratum: Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)

PubMed Journal of Clinical Oncology RSSOriginal source
🌍Mediaseqens.comTier 2 · Direct publisher

SEQENS to launch PeptiCode™ HP-9: the first European biotech Hexapeptide-9

SeqensOriginal source
🇯🇵pharma_equipmentprodcms.ulvac.co.jpTier 2 · Direct publisher

ULVAC Group to Sponsor ICEP-HBS 2026 as a Gold Sponsor

Ulvac (Pharma)Original source
🌍Industryicecure-medical.comTier 1 · Company source

Join IceCure at ASBrS 2026: Cryoablation for Breast Cancer in Low-Risk Patients

IceCure MedicalOriginal source